Bio & Healthcare

We produce and supply chemical materials such as API (Active Pharmaceutical Ingredients) and advanced intermediates through our pharmaceutical business, and CleanBio antibacterial in our specialty chemical business.

As a global top-tier company, we lead the product market and strive to develop new biopharmaceuticals based on our accumulated experiences and capabilities.

Our mission is to become a global leader in life science innovation from bio to chemicals.

We introduce new drugs through partnerships with leading pharmaceutical companies and develop and supply various prescription drugs in respiratory medicine, dermatology, pediatrics, and orthopedics. We also supply various over-the-counter drugs and health functional food products, including Apniben Q, the first mouthwash-type stomatitis treatment, and Bicogreen S Tablet, a three-component constipation treatment.

Our main products in each field maintain top positions in market share and are recognized for their value.

KOLON PHARMA aims to become a total healthcare company by developing differentiated medicines and entering various healthcare markets.

KOLON Tissuegene is at the forefront of next-generation healthcare, offering breakthrough solutions to degenerative diseases through innovative cell and gene therapy. Our proprietary TG-C platform promotes cartilage regeneration and inhibits disease progression—laying the groundwork for a new era in regenerative medicine. In October 2001, we secured a U.S. patent for TGF-1-based gene therapy, validating our leadership in therapeutic gene science. Our osteoarthritis treatment, TG-C, is designed to reduce pain, restore function, and enhance quality of life for patients worldwide. Driven by a commitment to continual R&D, KOLON Tissuegene is shaping a healthier future and establishing itself as a global leader in the advanced medical landscape.